Table 2.

Subject Characteristics and Cholesterol Changes by Trial

Trial *	Mean Age,years	Proportion ofMale PatientsEnrolled, %	Baseline TotalCholesterol,mg/dL	BaselineLDL Cholesterol,mg/dL	TotalCholesterolChange, †%	LDLCholesterolChange, †%
ACAPS 8	62	51	236	156	−15	−21
KAPS 9	57	100	259	189	−22	−32
PLAC-II 10	62	85	235	166	−21	−29
CAIUS 11	55	53	261	181	−18	−24
WOSCOP 15	55	100	272	192	−20	−26
LR 16	62	72	203	128	IR	−36
MARS 17	58	91	235	166	−30	−37
PLAC-I 18	57	78	231	164	−21	−29
4S 43	59	82	261	188	−26	−36
REGRESS 44	56	100	234	166	−19	−26
PMSG 45	55	77	265	180	−18	−26
CARE 46	59	86	209	139	−20	−28
CCAIT 52	53	81	250	173	−20	−28

^*Abbreviations are defined in the first footnote to Table 1.

^†Percentage reduction from baseline in treated patients compared with controls. A negative change implies a greater cholesterol reduction from baseline on statin therapy as compared to control; LDL indicates low-density lipoprotein; IR, insufficient information reported to permit calculation.